Supreem Pharma launches superfoods brand

Mr. S.N. Rao said Supreem Pharma is getting into Superfoods with a vision to fill the void that exists in the nutrition intake to enhance healthy living. The Company has dived deep into the science of food and has developed products which will help to fill the gap.

Supreem Pharmaceuticals Mysore Pvt. Ltd. achieved a turnover of Rs. 68 Crores last financial year. The growth CAGR has been over 20% Turnover & profitability over the last 5 years.

This financial year with the launch of consumer products division Supreem Super Foods the company hopes to achieve a combined turnover of around Rs. 90-100 Crores. Supreem Pharmaceuticals is investing over Rs. 25 Crores over next 5 years to build the Consumer business to achieve a CAGR of over 30% in the next 5 years to reach a combined turnover of Rs. 250+ Crores with both the divisions giving approximately equal share to the business and consumer business.

"These products are made from natural ingredients which aim to boost healthy living with no side effects," the company said in a release.

Speaking at the press conference to announce the launch of this new range, S.N. Rao, Chairman & MD of Supreem said "Healthy living is the need of the hour. Everything we do is motivated by our desire to be healthy and happy. There can be no substitute for this. Supreem Super Foods is on a mission to raise the bar for healthy living by combining innovation, experience, and vision. We have developed & are further researching smart, sustainable Superfoods. These products will not only enhance our diet, but help people realize their full potential. Living Healthy is essential and this can be ensured by optimal physical, mental, and healthy food habits."

He also added, "Through the launch of this new consumer division, we aim to invest over Rs 80 crores over the next three years. This would lead to a direct and indirect employment to a tune of 1500 - 2000 during this period."

Supreem Super Foods aims to expand their product range by the end of this financial year to over 50 products and over 100 products by the end of next financial year.

Read also: Biological E seeks DCGI nod for phase-3 trial of Corbevax as booster dose